A systematic review of the role of bisphosphonates in metastatic disease - PubMed (original) (raw)
Review
doi: 10.3310/hta8040.
Affiliations
- PMID: 14960258
- DOI: 10.3310/hta8040
Free article
Review
A systematic review of the role of bisphosphonates in metastatic disease
J R Ross et al. Health Technol Assess. 2004.
Free article
Abstract
Objectives: To identify evidence for the role of bisphosphonates in malignancy for the treatment of hypercalcaemia, prevention of skeletal morbidity and use in the adjuvant setting. To perform an economic review of current literature and model the cost effectiveness of bisphosphonates in the treatment of hypercalcaemia and prevention of skeletal morbidity.
Data sources: Electronic databases (1966-June 2001). Cochrane register. Pharmaceutical companies. Experts in the field. Handsearching of abstracts and leading oncology journals (1999-2001).
Review methods: Two independent reviewers assessed studies for inclusion, according to predetermined criteria, and extracted relevant data. Overall event rates were pooled in a meta-analysis, odds ratios (OR) were given with 95% confidence intervals (CI). Where data could not be combined, studies were reported individually and proportions compared using chi-squared analysis. Cost and cost-effectiveness were assessed by a decision analytic model comparing different bisphosphonate regimens for the treatment of hypercalcaemia; Markov models were employed to evaluate the use of bisphosphonates to prevent skeletal-related events (SRE) in patients with breast cancer and multiple myeloma.
Results: For acute hypercalcaemia of malignancy, bisphosphonates normalised serum calcium in >70% of patients within 2-6 days. Pamidronate was more effective than control, etidronate, mithramycin and low-dose clodronate, but equal to high dose clodronate, in achieving normocalcaemia. Pamidronate prolongs (doubles) the median time to relapse compared with clodronate or etidronate. For prevention of skeletal morbidity, bisphosphonates compared with placebo, significantly reduced the OR for fractures (OR [95% CI], vertebral, 0.69 [0.57-0.84], non-vertebral, 0.65 [0.54-0.79], combined, 0.65 [0.55-0.78]) radiotherapy 0.67 [0.57-0.79] and hypercalcaemia 0.54 [0.36-0.81] but not orthopaedic surgery 0.70 [0.46-1.05] or spinal cord compression 0.71 [0.47-1.08]. However, reduction in orthopaedic surgery was significant in studies that lasted over a year 0.59 [0.39-0.88]. Bisphosphonates significantly increased the time to first SRE but did not affect survival. Subanalyses were performed for disease groups, drugs and route of administration. Most evidence supports the use of intravenous aminobisphosphonates. For adjuvant use of bisphosphonates, Clodronate, given to patients with primary operable breast cancer and no metastatic disease, significantly reduced the number of patients developing bone metastases. This benefit was not maintained once regular administration had been discontinued. Two trials reported significant survival advantages in the treated groups. Bisphosphonates reduce the number of bone metastases in patients with both early and advanced breast cancer. Bisphosphonates are well tolerated with a low incidence of side-effects. Economic modelling showed that for acute hypercalcaemia, drugs with the longest cumulative duration of normocalcaemia were most cost-effective. Zoledronate 4 mg was the most costly, but most cost-effective treatment. For skeletal morbidity, Markov models estimated that the overall cost of bisphosphonate therapy to prevent an SRE was GBP250 and GBP1500 per event for patients with breast cancer and multiple myeloma, respectively. Bisphosphonate treatment is sometimes cost-saving in breast cancer patients where fractures are prevented.
Conclusions: High dose aminobisphosphonates are most effective for the treatment of acute hypercalcaemia and delay time to relapse. Bisphosphonates significantly reduce SREs and delay the time to first SRE in patients with bony metastatic disease but do not affect survival. Benefit is demonstrated after administration for at least 6-12 months. The greatest body of evidence supports the use of intravenous aminobisphosphonates. Further evidence is required to support use in the adjuvant setting.
Similar articles
- Bisphosphonates for breast cancer.
Pavlakis N, Schmidt R, Stockler M. Pavlakis N, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034900 Updated. Review. - Bisphosphonates for breast cancer.
Pavlakis N, Stockler M. Pavlakis N, et al. Cochrane Database Syst Rev. 2002;(1):CD003474. doi: 10.1002/14651858.CD003474. Cochrane Database Syst Rev. 2002. PMID: 11869664 Updated. Review. - Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Mhaskar R, et al. Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Cochrane Database Syst Rev. 2012. PMID: 22592688 Updated. Review. - Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Mhaskar R, et al. Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4. Cochrane Database Syst Rev. 2017. PMID: 29253322 Free PMC article. Review. - Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. O'Carrigan B, et al. Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4. Cochrane Database Syst Rev. 2017. PMID: 29082518 Free PMC article. Review.
Cited by
- Dynamic alterations in M2 macrophage subtypes enhance flap expansion efficiency and tissue regeneration.
Wang X, Zhao M, Wang Q, Wang J, Wang T. Wang X, et al. Cell Biochem Biophys. 2024 Jun;82(2):859-871. doi: 10.1007/s12013-024-01237-5. Epub 2024 Mar 5. Cell Biochem Biophys. 2024. PMID: 38441826 - Current Overview of Treatment for Metastatic Bone Disease.
Tsukamoto S, Kido A, Tanaka Y, Facchini G, Peta G, Rossi G, Mavrogenis AF. Tsukamoto S, et al. Curr Oncol. 2021 Aug 29;28(5):3347-3372. doi: 10.3390/curroncol28050290. Curr Oncol. 2021. PMID: 34590591 Free PMC article. Review. - Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review.
Andronis L, Goranitis I, Bayliss S, Duarte R. Andronis L, et al. Pharmacoeconomics. 2018 Mar;36(3):301-322. doi: 10.1007/s40273-017-0595-0. Pharmacoeconomics. 2018. PMID: 29224174 - Spinal Compression Fracture Management: A Review of Current Treatment Strategies and Possible Future Avenues.
Genev IK, Tobin MK, Zaidi SP, Khan SR, Amirouche FML, Mehta AI. Genev IK, et al. Global Spine J. 2017 Feb;7(1):71-82. doi: 10.1055/s-0036-1583288. Epub 2017 Feb 1. Global Spine J. 2017. PMID: 28451512 Free PMC article. Review. - Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A, DeNichilo MO, Panagopoulos V, Zinonos I, Liapis V, Hay S, Ingman W, Ponomarev V, Atkins G, Findlay D, Zannettino A, Evdokiou A. Zysk A, et al. Cancer Lett. 2017 Feb 1;386:141-150. doi: 10.1016/j.canlet.2016.11.013. Epub 2016 Nov 16. Cancer Lett. 2017. PMID: 27865798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical